1.
Weidinger S, Pink A, Francisco J, Kurbasic A, Olsen C, Vilsbøll A, de Bruin Weller M. Tralokinumab Improves Clinically Relevant Outcome Measures: A Post Hoc Analysis of ECZTRA 3, A Randomized Clinical Trial in Patients with Moderate-To-Severe Atopic Dermatitis. J of Skin [Internet]. 2020Oct.27 [cited 2021Jan.25];4(6):s100. Available from: https://jofskin.org/index.php/skin/article/view/1077